Ultragenyx Pharmaceutical (RARE) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q4 2024 value amounting to $112.5 million.
- Ultragenyx Pharmaceutical's Accumulated Depreciation & Amortization rose 3486.89% to $112.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $112.5 million, marking a year-over-year increase of 3486.89%. This contributed to the annual value of $112.5 million for FY2024, which is 3486.89% up from last year.
- According to the latest figures from Q4 2024, Ultragenyx Pharmaceutical's Accumulated Depreciation & Amortization is $112.5 million, which was up 3486.89% from $83.4 million recorded in Q4 2023.
- In the past 5 years, Ultragenyx Pharmaceutical's Accumulated Depreciation & Amortization ranged from a high of $112.5 million in Q4 2024 and a low of $37.4 million during Q4 2020
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $63.4 million (2022), whereas its average is $69.3 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first skyrocketed by 4388.18% in 2020, then surged by 2666.57% in 2022.
- Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Accumulated Depreciation & Amortization stood at $37.4 million in 2020, then skyrocketed by 33.82% to $50.0 million in 2021, then increased by 26.67% to $63.4 million in 2022, then surged by 31.59% to $83.4 million in 2023, then soared by 34.87% to $112.5 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $112.5 million for Q4 2024, versus $83.4 million for Q4 2023 and $63.4 million for Q4 2022.